Associated conditions in small fiber neuropathy - a large cohort study and review of the literature

B T A de Greef, J G J Hoeijmakers, C M L Gorissen-Brouwers, M Geerts, C G Faber, I S J Merkies, B T A de Greef, J G J Hoeijmakers, C M L Gorissen-Brouwers, M Geerts, C G Faber, I S J Merkies

Abstract

Background and purpose: Small fiber neuropathy (SFN) is a common disorder leading to neuropathic pain and autonomic symptoms. The objective of this study was to investigate associated conditions in a large cohort of SFN patients and compare the prevalence to healthy individuals.

Methods: A total of 921 patients with pure SFN were screened according to a standardized comprehensive diagnostic algorithm and compared with literature findings.

Results: No associated condition could be found in 53% of the patients. Autoimmune diseases, sodium channel gene mutations, diabetes mellitus including glucose intolerance, and vitamin B12 deficiencies were more prevalent than reported literature findings, followed by alcohol abuse, chemotherapy, monoclonal gammopathy of undetermined significance, and haemochromatosis. In patients who were already known with a possible underlying condition at screening, additional underlying conditions were still found in another 26.7% of patients.

Conclusions: Based on these results, it is recommended that patients with pure SFN are screened at least for autoimmune diseases, sodium channel gene mutations, diabetes mellitus including glucose intolerance, and vitamin B12 deficiency, even when they already have a potential underlying condition at referral.

Keywords: associated conditions; neuropathic pain; small fiber neuropathy.

© 2017 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Figures

Figure 1
Figure 1
Flowchart of inclusion/exclusion. IENFD, intraepidermal nerve fiber density; SFN, small fiber neuropathy; TTT, temperature threshold testing.
Figure 2
Figure 2
Prevalence of possible underlying causes in patients with SFN (n = 921). *Glucose intolerance was only tested in 493 patients instead of 921. Immunology: sarcoidosis, Sjogren's disease, coeliac disease, other autoimmune diseases and abnormal immunological laboratory findings (antinuclear antibodies, anti‐neutrophil cytoplasmic antibodies, monoclonal gammopathy, soluble interleukin‐2 receptor, anti‐tissue transglutaminase and anti‐extractable nuclear antigen antibodies). MGUS, monoclonal gammopathy of undetermined significance; SCN, sodium voltage‐gated channels.

References

    1. Hoeijmakers JG, Faber CG, Lauria G, et al Small‐fibre neuropathies − advances in diagnosis, pathophysiology and management. Nat Rev Neurol 2012; 8: 369–379.
    1. Bakkers M, Faber CG, Hoeijmakers JG, et al Small fibers, large impact: quality of life in small‐fiber neuropathy. Muscle Nerve 2014; 49: 329–336.
    1. Tesfaye S, Boulton AJ, Dyck PJ, et al Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285–2293.
    1. Brouwer BA, Merkies IS, Gerrits MM, et al Painful neuropathies: the emerging role of sodium channelopathies. J Peripher Nerv Syst 2014; 19: 53–65.
    1. Schaefer C, Mann R, Sadosky A, et al Health status, function, productivity, and costs among individuals with idiopathic painful peripheral neuropathy with small fiber involvement in the United States: results from a retrospective chart review and cross‐sectional survey. J Med Econ 2014; 17: 394–407.
    1. de Greef BT, Hoeijmakers JG, Wolters EE, et al No Fabry disease in patients presenting with isolated small fiber neuropathy. PLoS One 2016; 11: e0148316.
    1. Faber CG, Hoeijmakers JG, Ahn HS, et al Gain of function NaV1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol 2012; 71: 26–39.
    1. Lauria G, Bakkers M, Schmitz C, et al Intraepidermal nerve fiber density at the distal leg: a worldwide normative reference study. J Peripher Nerv Syst 2010; 15: 202–207.
    1. Bakkers M, Faber CG, Reulen JP, et al Optimizing temperature threshold testing in small‐fiber neuropathy. Muscle Nerve 2015; 51: 870–876.
    1. Hovaguimian A, Gibbons CH. Diagnosis and treatment of pain in small‐fiber neuropathy. Curr Pain Headache Rep 2011; 15: 193–200.
    1. Devigili G, Tugnoli V, Penza P, et al The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 2008; 131: 1912–1925.
    1. Lauria G. Small fibre neuropathies. Curr Opin Neurol 2005; 18: 591–597.
    1. Federa . (accessed 18/05/2017).
    1. Peters MJ, Bakkers M, Merkies IS, et al Incidence and prevalence of small‐fiber neuropathy: a survey in the Netherlands. Neurology 2013; 81: 1356–1360.
    1. Lang M, Treister R, Oaklander AL. Diagnostic value of blood tests for occult causes of initially idiopathic small‐fiber polyneuropathy. J Neurol 2016; 263: 2515–2527.
    1. Lehmann HC, Meyer Zu Horste G, Kieseier BC, et al Pathogenesis and treatment of immune‐mediated neuropathies. Ther Adv Neurol Disord 2009; 2: 261–281.
    1. Rijkers GT, Batstra MR, Allebes W, et al Auto‐immuunziekten. Ned Tijdschr Klin Chem Labgeneesk 2006; 31: 246–248.
    1. Mekkes JR. Sarcoidosis. 2014. (accessed 18/05/2017).
    1. Tincani A, Andreoli L, Cavazzana I, et al Novel aspects of Sjogren's syndrome in 2012. BMC Med 2013; 11: 93.
    1. Maag‐Darm‐Leverartsen NVv . Guideline coeliac disease and dermatitis herpetiformis. 2008.
    1. Dib‐Hajj SD, Tyrrell L, Black JA, et al NaN, a novel voltage‐gated Na channel, is expressed preferentially in peripheral sensory neurons and down‐regulated after axotomy. Proc Natl Acad Sci U S A 1998; 95: 8963–8968.
    1. Faber CG, Lauria G, Merkies IS, et al Gain‐of‐function Nav1.8 mutations in painful neuropathy. Proc Natl Acad Sci U S A 2012; 109: 19444–19449.
    1. Huang J, Han C, Estacion M, et al Gain‐of‐function mutations in sodium channel Na(v)1.9 in painful neuropathy. Brain 2014; 137: 1627–1642.
    1. Hoeijmakers JG, Faber CG, Merkies IS, et al Painful peripheral neuropathy and sodium channel mutations. Neurosci Lett 2015; 596: 51–59.
    1. Estacion M, Han C, Choi JS, et al Intra‐ and interfamily phenotypic diversity in pain syndromes associated with a gain‐of‐function variant of NaV1.7. Mol Pain 2011; 7: 92.
    1. Boulton AJ, Vinik AI, Arezzo JC, et al Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956–962.
    1. National Public Health Compass − Diabetes Mellitus. 2014. (accessed 21/09/2017).
    1. Singleton JR, Smith AG, Bromberg MB. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001; 24: 1225–1228.
    1. Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001; 24: 1448‐1453.
    1. National Public Health Compass − Alcohol dependence. 2010. (accessed 18/05/2017).
    1. Mellion ML, Silbermann E, Gilchrist JM, et al Small‐fiber degeneration in alcohol‐related peripheral neuropathy. Alcohol Clin Exp Res 2014; 38: 1965–1972.
    1. Brewer JR, Morrison G, Dolan ME, et al Chemotherapy‐induced peripheral neuropathy: current status and progress. Gynecol Oncol 2016; 140: 176–183.
    1. Ramchandren S, Lewis RA. An update on monoclonal gammopathy and neuropathy. Curr Neurol Neurosci Rep 2012; 12: 102–110.
    1. Eisele L, Durig J, Huttmann A, et al Prevalence and progression of monoclonal gammopathy of undetermined significance and light‐chain MGUS in Germany. Ann Hematol 2012; 91: 243–248.
    1. Kyle RA, Therneau TM, Rajkumar SV, et al Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362–1369.
    1. Crawford J, Eye MK, Cohen HJ. Evaluation of monoclonal gammopathies in the ‘well’ elderly. Am J Med 1987; 82: 39–45.
    1. European Association for the Study of the Liver . EASL clinical practice guidelines for HFE hemochromatosis. J Hepatol 2010; 53: 3–22.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren